Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: Role of GPR120-mediated connexin43 phosphorylation

Wei-Ting Chen1 | Syue-yi Chen1 | De-Wei Wu2 | Cheng-Che Lee3 | Tsung-Ming Lee1,4

Abstract
The ω-3 fatty acids exert as an antioxidant via the G protein-coupled receptor 120 (GPR120). Icosapent ethyl, a purified eicosapentaenoic acid, showed a marked reduction in sudden cardiac death. Connexin43 is sensitive to redox status. We assessed whether icosapent ethyl attenuates fatal arrhythmias after myocardial infarction, a status of high oxidative stress, through increased connexin43 expression and whether the GPR120 signalling is involved in the protection. Male Wistar rats after ligation coronary artery were assigned to either vehicle or icosapent ethyl for 4 weeks. The postinfarction period was associated with increased oxidative-nitrosative stress. In concert, myocardial connexin43 levels revealed a significant decrease in vehicle-treated infarcted rats compared with sham. These changes of oxidative-nitrosative stress and connexin43 levels were blunted after icosapent ethyl administration. Provocative arrhythmias in the infarcted rats treated with icosapent ethyl were significantly improved than vehicle. Icosapent ethyl significantly increased GPR120 compared to vehicle after infarction. The effects of icosapent ethyl on superoxide and connexin43 were similar to GPR120 agonist GW9508. Besides, the effects of icosapent ethyl on oxidative-nitrosative stress and connexin43 phosphorylation were abolished by administering AH-7614, an inhibitor of GPR120. SIN-1 abolished the Cx43 phosphorylation of icosapent ethyl without affecting GPR120 levels. Taken together, chronic use of icosapent ethyl after infarction is associated with up-regulation of connexin43 phosphorylation through a GPR120-dependent antioxidant pathway and thus plays a beneficial effect on arrhythmogenic response to programmed electrical stimulation.

Keywords
arrhythmias, connexin43, G protein-coupled receptor 120, myocardial infarction, ω-3 polyunsaturated fatty acids
1 | INTRODUCTION

ω-3 polyunsaturated fatty acids (PUFAs) have been identified as vital nutrients to provide energy and play important roles in signalling transduction that might be able to offer benefits in a wide range of diseases. Epidemiological studies have shown that the mortality following myocardial infarction (MI) was reduced by 29% in the group advised to consume oily fishes compared with the non-fish groups during the follow-up of 2 years.¹ This reduced mortality was not associated with reduced ischaemic cardiovascular events or levels of total cholesterol. Antiarrhythmic effects of ω-3 PUFAs may play a role in reducing mortality including sudden cardiac death after MI.² Increased content of ω-3 PUFAs eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA) in red blood cells has been associated with a markedly reduced risk for sudden cardiac death.³ A recent guideline suggested that benefits of ω-3 PUFAs may be obtained through seafood consumption as with dietary supplementation.⁴ However, some studies have not reported a cardioprotective effect with ω-3 PUFA treatment, and animal model studies have even reported a proarrhythmic effect during acute regional myocardial ischaemia.⁵ Raitt et al⁶ reported that recurrent ventricular fibrillation or ventricular tachycardia occurred more often in the ω-3 PUFA group in patients with implantable defibrillators and may be proarrhythmic. Thus, the effect of ω-3 PUFAs on ventricular arrhythmia remains undetermined and more studies are required.

Basic research has shown that enrichment of myocardial membranes with ω-3 PUFAs reduces arrhythmic vulnerability.⁷ Although the long-chain ω-3 PUFAs have been shown to incorporate into membrane phospholipids, resulting in changes in gene expression profiles,⁸ EPA has been shown to be able to attenuate superoxide production and prevent vascular calcification in klotho mutant mice.⁹ Furthermore, Resolvin E1, a downstream mediator derived from EPA, can suppress reactive oxygen species (ROS) production at low concentrations.¹⁰ Thus, we hypothesized that EPA has beneficial effects on postinfarction arrhythmias by attenuating ROS production.

Connexin43 (Cx43) is the major structural protein of ventricular gap junctions, and a significant decrease in Cx43 causes sudden arrhythmic death.¹¹ Reduction of gap junctions in cardiac injury is associated with increased arrhythmogenicity.¹² Increased Cx43 levels by gene transfer ameliorate arrhythmia susceptibility in the border zone after MI.¹³ Previous studies have shown that ROS production reduces Cx43 at intercalated discs through competition with activated c-Src and increases ventricular arrhythmias in a mouse model of cardiac renin-angiotensin system activation.¹⁴ The G protein-coupled receptor 120 (GPR120) is an ω-3 fatty acid receptor which is up-regulated when EPA is administered at micromolar concentrations.¹⁵ GPR120 was highly expressed in the myocardium. The high level of GPR120 expression in myocardium indicates that GPR120 might play an important role in cardiomyocytes, such as antioxidation. Very recently, GPR120 activation has been shown to regulate redox status via GPR120-nuclear factor E2-related factor 2 (Nrf2) crosstalk mechanism.¹⁶ GPR120 gene knockdown by siRNA cancelled effects of EPA on ROS production,¹⁷ implying that GPR120 mediated the inhibitory effects of EPA on ROS production. Intake of ω-3 PUFAs was associated with up-regulation of Cx43 in diabetic¹⁸ and hypertensive¹⁹ animals. However, the role of ω-3 PUFAs in modifying Cx43 after MI has not previously been described. Therefore, in this study, we evaluated whether the administration of EPA could attenuate arrhythmias postinfarction through GPR120 and by increasing the expression of Cx43. The aims of this study were to (a) investigate whether the chronic administration of icosapent ethyl (IPE), a highly purified synthetic derivative of EPA, could attenuate arrhythmias by enhancing the expression of Cx43; and (b) assess the role of GPR120 in regulating the expression of Cx43 in a rat MI model using an agonist and antagonist of GPR120.

2 | METHODS

The animal experiment was approved and conducted in accordance with the local ethical review committee on animal care of the China Medical University and conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

2.1 | Animals

2.1.1 | Experiment 1: in vivo

The anterior descending arteries of male Wistar rats (200-250 g) were ligated as previously reported,²⁰ causing left ventricular (LV) free wall infarction. Rats were randomly assigned into either vehicle (saline) group or IPE (VASCEPA®, 0.3 g/kg per day; Amarin Pharma Inc) by gastric intubation in a final volume of 1.0 mL once a day. Rats were fed with IPE at a dose equivalent to the maximum clinical dose of 4 g/d based on body surface area comparison. Our intention was to achieve effects closer to levels observed in patients treated with prescription EPA supplementation in clinical trials.²¹ Tap water and standard diet were provided ad libitum.

Treatment with the drug was started 24 hours after infarction by daily oral gavage, as maximum benefits of the treatment would be achieved at this time point.²² The study was conducted over a 4-week period, as most (70%-80%) of the myocardial remodelling process in rats occurs within 3 weeks.²³ Sham-operated rats were used as controls to rule out the possible direct effect of the drug itself on the phosphorylation of Cx43. To eliminate the pharmacological actions of the drug, treatment was stopped approximately 24 hours prior to the end of the experiment.
2.1.2 | Experiment 2: ex vivo

To elucidate the potential role of GPR120 in mediating ROS, we performed ex vivo experiments. Four weeks after induction of MI by coronary ligation, infarcted rat hearts were isolated and subjected to no treatment (vehicle), IPE (50 µmol/L), GW9508 (a GPR120 agonist, 5 µmol/L), AH-7614 (a GPR120 antagonist, 7 µmol/L), 28-[(3-phenoxypyphenyl)methyl]aminobenzenepropanoic acid, Tocris bioscience), IPE + AH-7614 (a GPR120 antagonist, 7 µmol/L), 4-methyl-N-9H-xanthen-9-ylbenzenesulfonyamide, Sigma-Aldrich). The concentration of IPE (50 µmol/L) used in this study was based on free fatty acid levels in patients who were taking 5 g/d fish oil, comparable to plasma levels found in populations consuming high dietary fish intake.24 In addition, to avoid the uncertainty in results with the in vitro use of an EPA membrane, we used GW9508, a synthetic GPR120 agonist. GW9508 is a small molecule composed of benzyl ring structures, and as such it is unlikely to be acylated into membrane lipids, thereby allowing the discrimination between receptor activation and membrane incorporation. AH-7614 has been shown to inhibit GPR120-mediated signals induced by a range of distinct fatty acids and synthetic GPR120 agonist ligands.25 AH-7614 is a simple xanthene-containing chemical, and this molecule does not block agonist effects at GPR40.26 Each heart was perfused with a non-circulating modified Tyrode’s solution as previously described.27 Drugs were infused for 1 hour, which was effective in attenuating ROS production.28 At the end of the study, all hearts (n = 5 per group) were used for ROS and Cx43 analysis in the remote zone (>2 mm outside the infarct).

2.1.3 | Experiment 3: ex vivo

Although results of the above study showed that IPE modulated ROS and Cx43 (see Section 3), the relationship between the two remained unclear. We employed 3-morpholinosydnonimine (SIN-1, a peroxynitrite generator) in an ex vivo experiment. Four weeks after MI had been induced by coronary artery ligation, the infarcted rat hearts were isolated and received treatment with IPE (50 µmol/L), IPE + SIN-1 (37 µmol/L) or no treatment (vehicle). The dose of SIN-1 was chosen as previous studies.29 The perfusion setting was the same as the Part 2. At the end of the study, all hearts (n = 5 each group) were used for measuring GPR120 and Cx43 levels.

2.2 | In vivo electrophysiological studies

At the end of the study, the rats were intraperitoneally anaesthetized with Zoletil (20 mg/kg body weight) and xylazine (9 mg/kg). To assess the potential arrhythmogenic risk of reduced Cx43 protein, we performed in vivo programmed electrical stimulation after left thoracotomy and artificial respiration. Body temperature was maintained at 37°C with a thermostatically controlled heating lamp. Programmed electrical stimulation was performed with electrodes sewn to the epicardial surface of the right ventricular outflow tract. Pacing pulses were generated from a Bloom stimulator (Fischer Imaging Corporation). To induce ventricular arrhythmias, pacing was performed at a cycle length of 120 ms (S1) for eight beats, followed by one to three extrastimuli (S2, S3 and S4) at shorter coupling intervals. The end-point of ventricular pacing was induction of ventricular tachyarrhythmia. Ventricular tachyarrhythmias including ventricular tachycardia and ventricular fibrillation were considered nonsustained when it lasted ≤15 beats and sustained when it lasted >15 beats. An arrhythmia scoring system was modified as previously described.23 0, noninducible preparations; 1, nonsustained tachyarrhythmias induced with three extrastimuli; 2, sustained tachyarrhythmias induced with three extrastimuli; 3, nonsustained tachyarrhythmias induced with two extrastimuli; 4, sustained tachyarrhythmias induced with two extrastimuli; 5, nonsustained tachyarrhythmias induced with one extrastimulus; 6, sustained tachyarrhythmias induced with one extrastimulus; and 7, tachyarrhythmias induced during the eight paced beats. If the heart stopped before the pacing, the arrhythmia score assigned to that heart was 8. When multiple forms of arrhythmias occurred in one heart, the highest score was used. The experimental protocols were typically completed within 10 minutes.

2.3 | Haemodynamics and infarct size measurements

At completion of the electrophysiological tests, the atria and the right ventricle were trimmed off, and the LV was rinsed in cold physiological saline, weighed and immediately frozen in liquid nitrogen after obtaining a coronal section of the LV for infarct size estimation. Each section was stained with haematoxylin and eosin, and trichrome. The infarction size was determined in sections taken from the equator of the LV. Infarct size was reported as an average of the proportions of LV endocardial and epicardial circumferences occupied by the infarct as previously described.27 With respect to clinical importance, only rats with large infarction (>30%) were selected for analysis. Haemodynamic parameters were measured (Appendix S1).

2.4 | In situ detection of superoxide and nitrotyrosine

To measure myocardial superoxide and nitrotyrosine production, we used in situ dihydroethidium (DHE) and anti-nitrotyrosine antibody. For a detailed method, please refer to the Appendix S1.

2.5 | Real-time RT-PCR of GPR120 and Cx43

GPR120 and Cx43 mRNAs were quantified by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) using TaqMan system with cyclophilin as a loading control. Sequence of PCR primers are shown in the Appendix S1.
2.6 Western Blot analysis of GPR120, ser368-phosphorylated Cx43 and total Cx43

For a detailed method, please refer to the Appendix S1.

2.7 Immunohistochemical studies of GPR120 and Cx43

In order to investigate the spatial distribution and quantification of GPR120 and Cx43, immunohistochemical analysis was conducted on LV muscles from the remote zone as Appendix S1.

2.8 Laboratory measurements

Blood samples from ascending aortas of the rats were collected at the end of the study, and serum was separated by centrifugation. To assure EPA levels more relevant to human populations, serum Resolvin E1 levels were measured by using a commercially available kit (MyBiosource, Inc) and following the manufacturer’s instructions.

Myocardial production of superoxide in the remote zone was evaluated with lucigenin (5 μmol/L bis-N-methylacridinium nitrate, Sigma)-enhanced chemiluminescence as reported in a previous study. The chemiluminescent signal was calculated by subtracting background activity and was expressed as counts/min/mg weight (cpm/mg).

2.9 Statistical analysis

Results were presented as mean ± SD. All statistical analyses were performed using SPSS software (SPSS, version 23.0). Differences among the groups of rats were tested by analysis of variance (ANOVA), with Bonferroni correction if there was a significant effect. Electrophysiological data (programmed electrical stimulation-induced arrhythmia scores) were compared using the Kruskal–Wallis test followed by the Mann–Whitney test. A P value < .05 was considered to indicate a statistically significant difference.

3 RESULTS

3.1 Part 1: in vivo

The average weight of rats did not differ among the four groups at baseline (data not shown) and at the end of the study (Table 1). The mortality rate was similar between the two infarcted groups during the experimental period. Relative heart weights corrected

| Parameters               | Sham | Infarction |
|--------------------------|------|------------|
|                          | Saline | IPE | Vehicle | IPE |
| No. of rats              | 10    | 10 | 12   | 12 |
| Mortality, n (%)         | 0 (0%) | 0 (0%) | 6 (33%) | 5 (29%) |
| Body weight, g           | 352 ± 21 | 378 ± 18 | 349 ± 16 | 373 ± 18 |
| Heart rate, bpm          | 399 ± 20 | 388 ± 19 | 403 ± 17 | 406 ± 17 |
| LVEESP, mm Hg            | 101 ± 5 | 102 ± 6 | 105 ± 8 | 107 ± 7 |
| LVEDP, mm Hg             | 6 ± 1  | 5 ± 3  | 19 ± 4* | 17 ± 5* |
| +dp/dt, mm Hg/s          | 6963 ± 364 | 7102 ± 376 | 2872 ± 342* | 3451 ± 304* |
| −dp/dt, mm Hg/s          | 6671 ± 337 | 6592 ± 392 | 2263 ± 296* | 2726 ± 318* |
| Infarct size, %          | ...   | ...  | 39 ± 3 | 40 ± 3 |
| LVW/BW, mg/g             | 2.06 ± 0.21 | 2.22 ± 0.25 | 3.35 ± 0.39* | 3.29 ± 0.38* |
| RVW/BW, mg/g             | 0.62 ± 0.12 | 0.65 ± 0.15 | 0.79 ± 0.11* | 0.69 ± 0.10* |
| LungW/BW, mg/g           | 4.22 ± 0.38 | 4.38 ± 0.29 | 5.98 ± 0.61* | 4.78 ± 0.45* |
| Resolvin E1, pg/mL       | 762 ± 142 | 19 877 ± 248* | 892 ± 172 | 21 634 ± 435* |

Note: Values are mean ± SD.
Abbreviations: BW, body weight; LungW, lung weight; LVEDP, left ventricular end-diastolic pressure; LVEESP, left ventricular end-systolic pressure; LVW, left ventricular weight; RVW, right ventricular weight.

*P < .05 compared with respective sham.
†P < .05 compared with the infarcted group treated with vehicle.
‡P < .05 compared with sham treated with saline.

Myocardial peroxynitrite formation was estimated by measuring the level of free nitrotyrosine (as a marker for peroxynitrite formation) by ELISA (Cayman Chemical) in myocardial homogenates.

TABLE 1 Cardiac morphology, haemodynamics and biochemistry at the end of study
for body weight at the end of the study (12 weeks of age) are presented in Table 1. Relative weights of the hearts corrected for body weight at the end of the study (4 weeks after infarction) are presented in Table 1. Four weeks postinfarction, the infarcted areas of the LVs were extensively replaced by scar tissue (Figure 1A). However, in the infarcted groups, the weights of the LVs including the septum were essentially unchanged after 4 weeks. The infarcted rats that received IPE treatment had a significantly lower lung weight/body weight ratio, an index of lung oedema, compared to the infarcted rats treated with vehicle. In addition, the $+\text{dp}/\text{dt}$ and $-\text{dp}/\text{dt}$ values were significantly higher in the IPE-treated infarcted group compared to the vehicle-treated infarcted group. However, there were no significant differences in LV end-systolic pressure, LV end-diastolic pressure and infarct size between the infarcted groups.

Besides, the levels of Resolvin E1, a bioactive oxygenated product of EPA, in the IPE-treated infarcted group was $21,634 \pm 435 \text{ pg/mL}$, significantly higher than vehicle ($892 \pm 172 \text{ pg/mL, } P < .0001$), implying the adequate dose of EPA used in this study.

### 3.1.1 Effect of IPE on GPR120 expression

We investigated GPR120 regulation in the heart of rats. GPR120 protein was significantly increased after MI compared with sham (Figure 1B). However, after administering IPE, GPR120 protein levels were further increased accompanied by a similar change of GPR120 immunohistochemical staining (Figure 1B-C). The changes of GPR120 mRNA mirrored those in GPR120 protein of Western blot (Figure 1D).

### 3.1.2 Effect of IPE on oxidative-nitrosative stress

Following MI, superoxide production assessed by lucigenin-enhanced chemiluminescence was markedly increased in the remote LV myocardium as compared with sham ($P < .001$, Figure 2A). Superoxide production significantly fell in IPE-treated infarcted rats compared with vehicle.

Dihydroethidium reacts with superoxide anions to form a specific nuclear red fluorescence as a marker of superoxide radical generation. As shown in Figure 2B, postinfarction remodelling markedly enhanced the intensity of the DHE staining in the remote zone compared with sham. However, the intensity of the fluorescent signal in the IPE-treated group was significantly reduced compared with the vehicle-treated group.

Similarly, LV nitrotyrosine levels in vehicle-treated infarcted rats significantly increased as compared to sham ($P < .001$, Figure 2C). Myocardial nitrotyrosine levels can be significantly reduced after administering IPE. Nitrotyrosine immunoreactivity, as evidenced

![Figure 1](image-url)
by increased brown staining (Figure 2D), was significantly increased after MI, which can be attenuated after adding IPE.

### 3.1.3 Effect of IPE on cardiac Cx43 phosphorylation

To investigate the cardiac Cx43 after infarction, we analysed immunofluorescence, Western blot and mRNA levels. The immunohistochemical analysis showed that in the sham group, sections revealed discontinuous punctate labelling for Cx43 primarily at intercalated discs between two adjacent cardiomyocytes. Infarction resulted in a significant decrease of 70% in the amount of Cx43 immunoreactive signals. The immunoreactive signal of Cx43 was significantly increased in IPE-treated infarcted rats compared to the vehicle-treated infarcted rats (Figure 3A).

Western blot showed that ventricular remodelling after MI was associated with significantly decreased levels of p-Cx43 (ser368) and total Cx43 in the remote zone (Figure 3B). In the IPE-treated infarcted group, this decrease in level of p-Cx43 (ser368) and total Cx43 levels was significantly attenuated compared with the vehicle-treated infarcted group, consistent with the immunohistochemical analysis.

The Cx43 mRNA level showed significant down-regulation in the remote zone after MI (Figure 3C). The Cx43 mRNA level showed a 21% up-regulation in the remote zone after adding IPE compared with those in the vehicle-treated infarcted rats ($P < .001$). Thus, the mRNA levels paralleled the changes in the tissue protein levels, implying that the production of Cx43 mRNA is an essential regulatory step to ensure its local activation.

### 3.1.4 Effect of IPE on arrhythmias

To further elucidate the physiological effect of increased Cx43 phosphorylation, ventricular pacing was performed. Sham-operated rats had low arrhythmia score (0.2 ± 0.3) (Figure 4). In contrast, myocardial infarcted rats had inducible ventricular tachyarrhythmias consisting of ventricular tachycardia and ventricular fibrillation by programmed stimulation. The inducibility of ventricular tachyarrhythmias was significantly decreased by IPE treatment compared to treatment with vehicle.

### 3.2 Part 2: ex vivo

#### 3.2.1 Experiment 2: IPE attenuates ROS and increased Cx43 levels in a GPR120-dependent pathway

The requirement of GPR120 in the regulation of ROS production was shown in infarcted rats from IPE and from the combination of IPE and AH-7614. As shown in Figure 5A, AH-7614 reversed the attenuated ROS levels compared with IPE alone, implying that GPR120 is a downstream molecule of IPE.

To further determine whether IPE is incorporated into the membrane phospholipids, we used the GPR120 agonist GW9508. As shown in Figure 5A-C, when infarcted hearts were treated with GW9508, the extent of antioxidation and increased Cx43 effect was similar to that of IPE. AH-7614 inhibited the increased Cx43 phosphorylation compared with IPE alone, confirming the critical role of GPR120 in regulation of ROS production and Cx43 levels.
3.2.2 | Experiment 3: the role of ROS signalling in IPE-mediated Cx43 phosphorylation

To elucidate the role of the superoxide signalling in IPE-mediated Cx43 phosphorylation, SIN-1 was assessed in an ex vivo model. Figure 6 shows that SIN-1 significantly reversed IPE-mediated Cx43 phosphorylation compared with IPE alone, whereas GPR120 levels were not affected following the administration of SIN-1. Thus, ROS were the upstream to modulate the Cx43 phosphorylation.

4 | DISCUSSIONS

In this study, we explored a novel mechanism by which antiarrhythmias by administering IPE were related to increased Cx43 phosphorylation via GPR120-mediated ROS production after infarction. To address the role of GPR120 in mediating IPE-attenuated ROS more directly, we used GPR120 antagonist and agonist to test the requirement for GPR120 to prevent MI-induced ROS. These results were consistent with the beneficial effects of IPE, as documented...
structurally by DHE, nitrotyrosine staining and immunofluorescence-stained Cx43; molecularly by myocardial Cx43 protein and mRNA levels; biochemically by tissue superoxide chemiluminescence, nitrotyrosine and resolving E1 levels; and functionally by improvement of pacing-induced ventricular tachyarrhythmias. Our study shows that nonpharmacological therapeutics with IPE inhibit postinfarcted arrhythmias in concentrations that are clinically relevant in both in vivo and ex vivo models. Our results were consistent with the notion that a high $\omega$-3 index is associated with a low-risk for sudden cardiac death.\textsuperscript{30}

Besides nutritional effects, $\omega$-3 PUFAs are well known to act as intracellular mediators. We showed that increased Cx43 phosphorylation may be an additional mechanism by which chronic treatment for 4 weeks with IPE may be effective therapeutics to improve fatal arrhythmias. Our conclusions are supported by 2 lines of evidence (Figure 7).

1. MI was associated with high oxidative stress, leading to Cx43 loss. The balance between oxidants and antioxidants was disrupted in favour of prooxidants in postinfarcted myocardial remodelling. The role of myocardial superoxide mediating myocardial Cx43 was confirmed by administering SIN-1. In this study, we demonstrated that SIN-1 abolished the increased IPE-mediated Cx43 phosphorylation. Our results confirmed and extended previous findings, showing that disturbances to the nitroso-redox balance can have a deleterious effect on Cx43 proteins.\textsuperscript{15} Pharmacologic or dietary interventions for correcting this imbalance may have a positive impact on arrhythmias.

2. IPE administration increased the mRNA and protein levels of GPR120. Free fatty acids are generated during lipolysis and enter the bloodstream to circulate throughout the body. Circulating free fatty acids not only provide substrate for energy production but importantly can also act as lipid sensors and mediate the expression of genes and proteins to regulate lipid and energy homeostasis in a diverse range of physiological and pathophysiological conditions. The rats fed with the high-fat diet significantly up-regulated the abundance of GPR120 mRNA in cardiac tissue,\textsuperscript{31} suggesting that the GRP120 could serve as a dietary fatty acid sensor sensitive to levels of serum fatty acids. Similarly, the GPR120 mRNA expression was significantly increased after administering DHA determined by RT-PCR analyses in mouse primary hepatocytes.\textsuperscript{32} Besides, the protein level of GPR120 has been shown to be increased significantly in RAW264.7 cells after EPA treatment,\textsuperscript{33} which was consistent with our findings. Regulatory mechanisms underlying the expression of GPR120 are not understood. Further investigation is required to resolve how IPE regulate the mRNA expression and protein levels of GPR120 in myocardium.

3. IPE as an antioxidant in myocardium was found to be GPR120-dependent. We found that IPE interacts with GPR120, which in turn attenuated oxidative and nitrative products; correspondingly, GPR120 participates significantly to increased Cx43 phosphorylation. This localization of GPR120 enables the clustering of cell surface receptors with downstream effector molecules. The ability of IPE to inhibit ROS was abolished in GPR120 antagonist. Presence of GPR120 antagonist during IPE exposure resulted in increased ROS production. These findings indicate that

---

**FIGURE 4** A, representative ventricular arrhythmias induced by ventricular pacing. Upper panel: infarcted rat treated with vehicle. Following 8 basic stimuli at a cycle length of 120 ms, sustained tachyarrhythmia was induced (score: 7). Lower panel: infarcted rat treated with IPE (score: 5). B, inducibility quotient of ventricular arrhythmias by programmed electrical stimulation 4 wk after MI. The number of animals in each group is indicated in parentheses. *P < .05 compared with sham; †P < .05 compared with the vehicle-treated infarcted group.

**FIGURE 5** Ex vivo studies. In a rat isolated heart model, the effect of GPR120 on superoxide anions and Cx43 levels is shown. A, dihydroethidium (DHE) staining (magnification 400x) and quantitative analysis. B, Immunofluorescent staining for Cx43 (magnification 400x). C, Western blot of phosphorylated Cx43 and total Cx43 protein. The effects of IPE on superoxide anions and Cx43 levels were reversed by AH-7614. The effects of GW9508 on superoxide anions and Cx43 levels were similar to those of IPA. Bar = 50 μm. Each point is an average of three separate experiments (n = 5 per group). *P < .05 compared with groups treated with vehicle, and IPE + AH-7614.
the inhibitory effect of IPE on ROS occurs via GPR120. Although previous studies have shown that ω-3 PUFAs also act through incorporation into cell membranes and modulation of intracellular signalling, the onset of these biological effects may take longer time. Our experiments with GW9508 showed rapid changes of signalling pathways within 1 hour, implying that activation of GPR120 is sufficient to prevent MI-induced ROS without affecting membrane lipid composition. Indeed, our results were consistent with the findings of Amos et al, showing that ω-3 PUFAs alter the balance of redox homeostasis by activation of the Nrf2 pathway.

As we showed here that postinfarction was associated with increased GPR120 expression, reactive oxygen and nitrogen species (RONS) activity was expected to be reduced if GPR120 was the only upstream to modulate the RONS levels. Indeed, a number of proteins have been reported to associate with RONS and regulate its activity, such as endothelin-1 and angiotensin II. These RONS-interacting proteins function to mediate the crosstalk of RONS with other cellular signalling pathways. Attenuated RONS production by increased GPR120 expression after MI alone might not have reached a threshold beyond which benefits occur. Thus, it is not surprising to know that the RONS activity is increased after MI, a status of high GPR120. Thus, increased GPR120 activity by either pharmacology or diet supplement may be as a novel therapeutic target.

### 4.1 Previous studies

The beneficial actions of ω-3 PUFAs on sudden death have been reported. However, in some studies ω-3 PUFA supplementation did not improve the cardiovascular events. The Alpha OMEGA and OMEGA randomized trials included patients who had suffered a MI, and neither showed any improvement in reducing the rate of major cardiovascular events following ω-3 PUFA supplementation. Similarly, the European Medicines Agency has confirmed that ω-3 PUFAs containing a combination of ethyl ester of EPA and DHA at a dose of 1 g/d is no longer recommended for secondary prevention of cardiovascular events after MI. The apparent discrepancy among precedent literature may be explained by dose and population, the key crucial factors that act synergistically to determining effective therapy. First, given a threshold dose effect of EPA, the low-dose supplementation with EPA (226 mg/d, 30; 460 mg/d, 30) cannot provide benefits in the cardiovascular events. Second, previous studies have shown that after a 6-week dietary intervention with ω-3 PUFAs PUFAs, ventricular tachycardias were reduced only in subjects with low levels of ω-3 PUFAs PUFAs. Thus, use of a low ω-3 index as an inclusion criterion may allow for more efficient interventional trials, and this may help to elucidate the mechanisms of action. Furthermore, EPA has been shown to enhance mitochondrial function only under conditions where mitochondrial dysfunction is evident. Ventricular remodelling after MI is a process during which mitochondrial dysfunction plays a role. Indeed, in the current study, we found improvements in reducing ventricular vulnerability in a condition of mitochondrial dysfunction when an adequate dose of EPA (approximately 4 g/d) was given to infarcted rats. The effectiveness of EPA used in this study was confirmed by the results that IPE increased Resolvin E1 levels. Our findings were consistent with previous studies, showing that supplementation studies providing 3.1-8.4 g EPA + DHA/d have reported 30%-55% decreases in the production of ROS by stimulated human neutrophils. Studies using lower doses of long-chain ω-3 PUFAs (0.55-2.3 g/d) failed to demonstrate effects on ROS production.

### 4.2 Other mechanisms

Although the present study suggests that the mechanisms of IPE-triggered ROS-mediated Cx43 expression, other potential mechanisms for antiarrhythmic effect of IPE need to be studied. First, Resolvin E1 possesses anti-inflammation activities via ChemR23 receptors by inhibiting polymorphonuclear leucocyte transendothelial migration and IL-12 production. Excessive inflammation has been linked to increased incidence of postinfarction arrhythmia. Given AH 7614, an GPR120 antagonist, blocked the antioxidation and reversed the increased Cx43 levels of IPE, the possibility of Resolvin E1 in attenuated arrhythmias is unlikely. Second, ω-3 PUFAs have been shown to inhibit NLRP3 inflammasome activation, which in turn reduces the downstream molecule of IL-1β. Given IL-1β reduced Cx43 protein, ω-3 PUFA administration may also preserve Cx43 protein by inhibition of NLRP3 inflammasome-IL-1β axis.

### 4.3 Clinical implication

Our results suggest that IPE would have antiarrhythmic effects. The results are complementary to the AHA recommendation that ω-3 PUFA supplementation is reasonable in patients with prior coronary artery disease. Traditional antiarrhythmic drug trials have yielded disappointing results, paradoxically precipitated by proarrhythmia. Potential synthetic agonists of GPR120 based on molecular modelling could be further explored to obtain clinical benefits. Our results may open new avenues in our thinking about the action of EPA-derivatives on critical processes like arrhythmias. Although meta-analysis showed that ω-3 PUFA supplements do not improve cardiovascular outcomes in patients with prior coronary heart disease, a very recent trial using the same agent as this study, Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), showed a marked reduction in cardiovascular events.
Study limitations

There are some limitations in the present study that have to be acknowledged. First, given the effect of EPA is both tissue and species specific, the implications may have limitations when extrapolating data from tissue to tissue or species to species. Second, all of the studies were conducted using pharmacological inhibition, and pharmacological inhibitors may have many potential nonspecific targets. It would be interesting to further evaluate in vivo relationships between the GPR120 pathway and the antiarrhythmic effect of IPE using GPR120 knockout animal models. However, the existing GPR120 knockout mouse models exhibit significant hyperglycaemia. Due to the potential confounding effects of life-long hyperglycaemia on arrhythmia, we chose to use a pharmacological approach to inhibit GPR120.

5 | CONCLUSIONS

These data show that IPE at human achievable doses presents beneficial effects on attenuating ROS by activating GPR120, which increased Cx43 phosphorylation after infarction. These effects probably are functionally important because they are linked to attenuated vulnerability of fatal arrhythmias.

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interest.

AUTHOR CONTRIBUTION

Wei-Ting Chen: Conceptualization (supporting); Project administration (supporting); Validation (supporting); Visualization (supporting); Writing-original draft (lead); Writing-review & editing (lead). Syue-yi Chen: Data curation (supporting); Formal analysis (supporting); Project administration (lead); Validation (supporting); Visualization (lead); Writing-original draft (supporting); Writing-review & editing (supporting). De-Wei Wu: Data curation (supporting); Methodology (supporting); Project administration (supporting); Visualization (supporting); Writing-original draft (supporting); Writing-review &
DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Tsung-Ming Lee https://orcid.org/0000-0002-3487-8749

REFERENCES

1. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction: diet and Reinfarction Trial (DART). Lancet. 1989;334:757-761.
2. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Grupo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897-1903.
3. Wilhelm M, Tobias R, Asskali F, et al. Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with heart failure. Am Heart J. 2008;155:971-977.
4. Rimm EB, Appel LJ, Chiuve SE, et al. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2018;138:e35-e47.
5. Coronel R, Wilms-Schopman FJ, Den Ruijter HM, et al. Dietary n-3 fatty acids promote arrhythmias during acute regional myocardial ischemia in isolated pig hearts. Cardiovasc Res. 2007;73:386-394.
6. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005;293:2884-2891.
7. London B, Albert C, Anderson ME, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007;116:e320-e335.
8. Calder PC. Long chain fatty acids and gene expression in inflammation and immunity. Curr Opin Clin Nutr Metabolic care. 2013;16:425-433.
9. Eclov JA, Qian Q, Redetzke R, et al. EPA, not DHA, prevents fibrosis in pressure overload-induced heart failure: potential role of free fatty acid receptor 4. J Lipid Res. 2015;56:2297-2308.
10. Nakamura K, Miura D, Saito Y, et al. Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice. PLoS One. 2017;12:e0181009.
11. Takamiya R, Fukunaga K, Arita M, et al. Resolvin E1 maintains macrophage function under cigarette smoke-induced oxidative stress. FEBS Open Bio. 2012;2:328-333.
12. Van Norstrand DW, Asimaki A, Rubinos C, et al. Connexin43 mutation causes heterogeneous gap junction loss and sudden infant death. Circulation. 2012;125:474-481.
13. Gutstein DE, Morley GE, Tamaddon H, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res. 2001;88:333-339.
14. Greener ID, Sasano T, Wan X, et al. Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction. J Am Coll Cardiol. 2012;60:1103-1110.
15. Sovari AA, Rutledge CA, Jeong EM, et al. Mitochondria oxidative stress, connexin43 remodeling, and sudden arrhythmic death. Circ ARRhythm Electrophysiol. 2013;6:623-631.
16. Miyamoto J, Hasegawa S, Kasubuchi M, Ichimura A, Nakajima A, Kimura I. Nutritional signaling via free fatty acid receptors. Int J Mol Sci. 2016;17:450.
17. Amos DA, Cook C, Santanam N. Omega 3 rich diet modulates energy metabolism via GPR120-Nrf2 crosslink in a novel antioxidant mouse model. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:466-488.
18. Anna Z, Angela S, Barbara B, et al. Heart-protective effect of n-3 PUFAs demonstrated in a rat model of diabetic cardiomyopathy. Mol Cell Biochem. 2014:389:219-227.
19. Radosinska J, Bacova B, Knezl V, et al. Dietary omega-3 fatty acids attenuate myocardial arrhythmogenic factors and propensity of the heart to lethal arrhythmias in a rodent model of human essential hypertension. J Hypertens. 2013;31:1876-1885.
20. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298-310.
21. Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3:225-234.
22. Xia QG, Chung O, Spitznagel H, et al. Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure. Cardiovasc Res. 2001;49:110-117.
23. Béláchard P, Savard P, Cardinal R, et al. Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol. 1994;23:505-513.
24. Jaudszus A, Gruen M, Watzl B, et al. Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells. J Lipid Res. 2013;54:923-935.
25. Parks SM, Chen G, Collins JL, et al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (F4A4/GPR120). Bioorg Med Chem Lett. 2014;24:3100-3103.
26. Wallterson KR, Hansen SVF, Hudson BD, et al. Probe-dependent negative allosteric modulators of the long-chain free fatty acid receptor F4A4. Mol Pharmacol. 2017;91:630-641.
27. Lee TM, Lin MS, Chang NC. Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts. J Am Coll Cardiol. 2008;51:1309-1318.
28. Graciano MF, Leonelli M, Curi R, Carpinielli A. Omega-3 fatty acids control production of superoxide and nitrogen oxide and insulin content in INS-1E cells. J Physiol Biochem. 2016;72:699-710.
29. Dutka TL, Mollica JP, Lamb GD. Differential effects of peroxynitrite on contractile protein properties in fast- and slow-twitch skeletal muscle fibers of rat. J Appl Physiol. 1985;110(7):705-716.
30. vonSchacky C. Omega-3 fatty acids vs. cardiac disease—the contribution of the omega-3 index. Cell Mol Biol. 2010;56:93-101.
31. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ. Diet-induced obesity up-regulates the abundance of GPR43 and GPR120 in a tissue specific manner. Cell Physiol Biochem. 2011;28:949-958.
32. On S, Kim HY, Kim HS, et al. Involvement of G-Protein-coupled receptor 40 in the inhibitory effects of docosahexaenoic acid on SREBP1-mediated lipogenic enzyme expression in primary hepatocytes. Int J Mol Sci. 2019;20:2625.
33. Yamada H, Umemoto T, Kakei M, et al. Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice. *Nutr Metab (Lond)*. 2017;14:33.

34. Reimers A, Jung H. The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders. *Ther Adv Psychopharmacol*. 2019;9:2045125319858901.

35. Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. *N Engl J Med*. 2010;363:2015-2026.

36. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. *Circulation*. 2010;122:2152-2159.

37. Metcalf RG, Sanders P, James MJ, Cleland LG, Young GD. Effect of dietary n-3 polyunsaturated fatty acids on the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. *Am J Cardiol*. 2008;101:758-761.

38. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. *Circ Res*. 2001;88:529-535.

39. Varming K, Schmidt EB, Svaneborg N, et al. The effect of n_3 fatty acids on neutrophil chemiluminescence. *Scand J Clin Lab Invest*. 1995;55:47-52.

40. Thompson PJ, Misso NLA, Passarelli M, Phillips MJ. The effect of eicosapentaenoic acid consumption on human neutrophil chemiluminescence. *Lipids*. 1991;26:1223-1226.

41. Luostarinen R, Saldeen T. Dietary fish oil decreases superoxide generation by human neutrophils: relation to cyclooxygenase pathway and lysosomal enzyme release. *Prost Leuk Essent Fatty Acids*. 1996;55:167-172.

42. Kew S, Banerjee T, Minihane AM, et al. Lack of effect of foods enriched with plant- or marine-derived n_3 fatty acids on human immune function. *Am J Clin Nutr*. 2003;77:1287-1295.

43. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J Exp Med*. 2000;192:1197-1204.

44. Arita M, Bianchini F, Aliberti J, et al. Stereocchemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J Exp Med*. 2005;201:713-722.

45. Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. *J Mol Cell Cardiol*. 2016;91:114-122.

46. Yan Y, Jiang W, Spinetti T, et al. Omega-3 fatty acids prevent inflammatory and metabolic disorder through inhibition of NLRP3 inflammasome activation. *Immunity*. 2013;38:1154-1163.

47. Baum JR, Dolmatova E, Tan A, Duffy HS. Omega 3 fatty acid inhibition of inflammatory cytokine-mediated Connexin43 regulation in the heart. *Front Physiol*. 2012;3:272.

48. Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. *Circulation*. 2017;135:e867-e884.

49. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11-22.

50. Jump DB. The biochemistry of n_3 polyunsaturated fatty acids. *J Biol Chem*. 2002;277:8755-8758.

51. Suckow AT, Polidori D, Yan W, et al. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. *J Biol Chem*. 2014;289:15751-15763.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.